<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cisplatin, doxorubicin, and methotrexate for non-metastatic high-grade osteosarcoma in young adults and children&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cisplatin, doxorubicin, and methotrexate for non-metastatic high-grade osteosarcoma in young adults and children<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Cisplatin, doxorubicin, and methotrexate for non-metastatic high-grade osteosarcoma in young adults and children<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="17%"></colgroup><colgroup width="32%"></colgroup><colgroup span="2" width="17%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="5"><strong>Cycle length:</strong> 5 weeks (cycles 1 through 4), 4 weeks (cycle 5 and 6).<br/> <strong>Duration of therapy:</strong> 6 cycles.</td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Week of treatment</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Cisplatin*</td> <td>60 mg/m<sup>2</sup> per day IV (total dose = 120 mg/m<sup>2</sup> per cycle)</td> <td>Dilute in 250 mL NS<sup>¶</sup> and administer over four hours. Do not administer with aluminum needles or sets.</td> <td> <p>Preoperative: Weeks 1 and 6.</p> Postoperative: Weeks 12 and 17.</td> <td>Days 1 and 2</td> </tr> <tr> <td>Doxorubicin*</td> <td>37.5 mg/m<sup>2</sup> per day IV (total dose = 75 mg/m<sup>2</sup> per cycle)</td> <td> <p>Dilute in 1000 mL NS<sup>¶</sup> and administer as a continuous IV infusion over 24 hours daily.</p> Alternative: Dilute with NS to a final concentration of 2 mg/mL and administer as an IV bolus over three to five minutes into a free-flowing IV infusion of NS or D5W.<sup>¶</sup> Final solution should be protected from light.</td> <td> <p>Preoperative: Weeks 1 and 6.</p> Postoperative: Weeks 12, 17, 22, and 26.</td> <td>Days 1 through 2</td> </tr> <tr> <td>Methotrexate*</td> <td>12 g/m<sup>2</sup> IV<sup>Δ</sup></td> <td>Dilute in 500 mL D5W<sup>¶</sup> and administer over four hours. Final solution should be protected from light.</td> <td> <p>Preoperative: Week 4, 5, 9, and 10.</p> Postoperative: Week 15, 16, 20, 21, 24, 25, 28, and 29.</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin</td> <td>15 mg orally, IV, or IM every six hours (adjust dose according to serum methotrexate concentrations<sup>◊</sup>)</td> <td>Begin 24 hours after start of methotrexate infusion and continue until serum methotrexate concentration is &lt;0.1 microM.<sup>[1]</sup></td> <td> <p>Preoperative: Week 4, 5, 9, and 10.</p> Postoperative: Week 15, 16, 20, 21, 24, 25, 28, and 29.</td> <td>Day 2: Begin 24 hours after start of methotrexate infusion and continue until serum methotrexate concentration is &lt;0.1 micromol/L<sup>[1]</sup></td> </tr> <tr class="divider_bottom"> <td>Surgery</td> <td> </td> <td> </td> <td>Week 11</td> <td> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="5">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Hydration</strong></td> <td colspan="4"> <ul> <li>Cisplatin: NS-based IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Alternative: Pretreatment hydration with 1 to 2 L of NS-based fluid infused for 8 to 12 hours prior to each dose of cisplatin.<sup>¶[2]</sup></li> <li>Refer to UpToDate topics on cisplatin nephrotoxicity.</li> <li>Methotrexate: Adequate IV fluid (approximately 125 to 150 mL/hour) with electrolytes and bicarbonate must be given to maintain adequate urine output and alkalinization for methotrexate clearance. A urine pH &gt;7 must be achieved before starting the methotrexate infusion and maintained until the methotrexate serum level is &lt;0.1 microM. </li> <li>Refer to UpToDate topics on therapeutic use and toxicity of high-dose methotrexate.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="4"> <ul> <li>Cisplatin plus doxorubicin: HIGH (&gt;90% risk of emesis).</li> <li>Methotrexate: LOW (10 to 30% risk of emesis).</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="4"> <ul> <li>There is no standard premedication regimen for cisplatin, doxorubicin, or methotrexate.</li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="4"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage with a large-volume, concentrated extravasation; avoid extravasation. Doxorubicin is a vesicant; avoid extravasation. Administer infusions of doxorubicin through a central venous line.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="4"> <ul> <li>The AOST 0331/EURAMOS-1 protocol recommended secondary prophylaxis with G-CSF after doxorubicin/cisplatin cycles if prior doxorubicin/cisplatin cycles were complicated by fever and neutropenia with noncatheter-related sepsis or prolonged hospitalization (&gt;7 days). However, many centers give G-CSF with each cycle of doxorubicin/cisplatin. If given, begin growth factor support at least 24 hours after completion of chemotherapy; if given daily, continue until WBC count ≥5000/mm<sup>3</sup> after the nadir, and discontinue at least two days prior to next course of chemotherapy.</li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction and third-space fluid collections</strong></td> <td colspan="4"> <ul> <li>A lower starting dose of cisplatin and methotrexate may be needed for patients with renal impairment, although the optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Many clinicians would decrease the initial dose of cisplatin for a creatinine clearance &lt;50 mL/min. A lower starting dose of doxorubicin and methotrexate may be needed for patients with liver impairment. Methotrexate should not be administered in the setting of severe liver impairment (total bilirubin &gt;4 × ULN).<sup>[3]</sup></li> <li>In the AOST0331 protocol: <ul> <li>For total bilirubin ≥1.25 mg/dL and &lt;2.1 mg/dL, doxorubicin doses were reduced by 25%;</li> <li>For total bilirubin ≥2.1 mg/dL and &lt;3.06 mg/dL, doxorubicin doses were reduced by 50%;</li> <li>For total bilirubin ≥3.06 mg/dL and &lt;5 mg/dL, doxorubicin doses were reduced by 75%; and</li> <li>For total bilirubin ≥5 mg/dL, doxorubicin was omitted.<sup>[1]</sup></li> </ul> </li> <li>For patients with third-space fluid collections (eg, ascites, pleural effusion), await resolution or perform drainage before initiating methotrexate.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency, conventional cytotoxic agents; and therapeutic use and toxicity of high-dose methotrexate.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiac issues</strong></td> <td colspan="4"> <ul> <li>Doxorubicin is associated with dose-dependent cardiomyopathy; the incidence is related to cumulative dose. The risk of developing congestive heart failure increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m<sup>2</sup>. Cardiac toxicity may occur at lower cumulative doses whether or not cardiac risk factors are present. Assess baseline LVEF prior to initiating therapy. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines.<sup>[2]</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Prevention of high-dose methotrexate toxicity</strong></td> <td colspan="4"> <ul> <li>Maintaining urine output, alkalinization of the urine, monitoring methotrexate concentrations, providing leucovorin rescue, identifying and avoiding drug-drug interactions (eg, use with penicillins, cephalosporins, nonsteroidal anti-inflammatory agents, proton-pump inhibitors, etc), and monitoring electrolytes and renal function are important in the prevention of methotrexate toxicity.</li> <li>Refer to UpToDate topics on therapeutic use and toxicity of high-dose methotrexate.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="5">Monitoring parameters:</td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>CBC with differential prior to treatment.</li> </ul> </td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>Assess electrolytes and liver and renal function prior to treatment and daily during treatment.</li> </ul> </td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>Baseline audiometry, monitor for hearing loss prior to each dose of cisplatin; repeat audiometry as clinically indicated.</li> </ul> </td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>Assess change in neurologic function prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>Assess patient for third-space fluid collection prior to treatment.</li> </ul> </td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity.</li> </ul> </td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>Monitor for clinically significant nausea and vomiting.</li> </ul> </td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>Monitor serum methotrexate concentration daily starting 24 hours after the start of the methotrexate infusion and continue until serum methotrexate level is &lt;0.1 microM. If toxic concentrations of methotrexate with reduced clearance occur in the setting of renal insufficiency, consider emergent use of glucarpidase.</li> <li>Refer to UpToDate topics on therapeutic use and toxicity of high-dose methotrexate.</li> </ul> </td> </tr> <tr> <td colspan="5"> <ul class="decimal_heading"> <li>Monitor daily fluid balance (intake and output), weight, CBC with differential, platelets, blood pressure, LFTs (AST, ALT, total bilirubin), and serum creatinine daily during and after methotrexate therapy until the methotrexate serum level is &lt;0.1 microM.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="5"> <ul class="decimal_heading"> <li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically during doxorubicin therapy as clinically indicated.</li> <li>Refer to UpToDate topics on clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity and prevention and management of anthracycline cardiotoxicity.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="5">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="4"> <ul> <li>For cycles of cisplatin plus doxorubicin, hold treatment until ANC is ≥750/microL and platelet count is ≥75,000/microL. If ANC and platelets recovery is ≤7 days, no dose adjustment is required. If recovery is delayed &gt;7 days or if there is febrile neutropenia with prolonged hospitalization, decrease the cisplatin dose by 25%.<sup>[1]</sup></li> <li>For high-dose methotrexate, if the ANC is &lt;250/microL or platelets are &lt;50,000/microL, hold methotrexate until adequate hematologic recovery occurs.<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Audiology</strong></td> <td colspan="4"> <ul> <li>For any hearing loss with a threshold &gt;30 dB at ≤2 kHz, discontinue cisplatin.<sup>[1]</sup></li> <li>Refer to UpToDate topics on overview of neurologic complications of platinum-based chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiotoxicity</strong></td> <td colspan="4"> <ul> <li>For LVEF &lt;50% or shortening fraction &lt;28%, repeat MUGA or echocardiogram in one week. If the MUGA or echocardiogram is within normal limits, then proceed with chemotherapy. If LVEF does not normalize after one week, omit all further doxorubicin.<sup>[1]</sup> There are no prospective data on the use of the cardioprotective agent dexrazoxane in osteosarcoma therapy, particularly in children. Dexrazoxane may be used if a 10% decrease in LVEF or similar decrease within the normal range of shortening fraction (as determined by echocardiogram) occurs. Some clinicians add dexrazoxane once cumulative doxorubicin dose reaches 225 to 300 mg/m<sup>2</sup>. If cardioprotection is used, doxorubicin should be administered daily over 15 minutes immediately following dexrazoxane.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Hepatotoxicity</strong></td> <td colspan="4"> <ul> <li>For elevated LFTs that are not methotrexate induced, delay methotrexate treatment for one week and administer methotrexate if ALT is &lt;10 times normal.</li> <li>For elevated LFTs that are probably methotrexate induced (ie, up to three weeks after methotrexate), it is expected that patients receiving high-dose methotrexate will develop hypertransaminasemia and occasionally hyperbilirubinemia. These elevations can last up to two weeks following the methotrexate infusion and should not be considered a toxicity requiring dose reduction or discontinuation of the drug. However, for total bilirubin &gt;1.5 times normal for longer than three weeks, discontinue methotrexate.<sup>[1]</sup></li> <li>Refer to UpToDate topics on therapeutic use and toxicity of high-dose methotrexate.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Mucositis, severe abdominal pain, diarrhea, and typhlitis</strong></td> <td colspan="4"> <ul> <li>For grade 4 mucositis or typhlitis or repeated grade 3 mucositis, hold cisplatin and doxorubicin until toxicity has resolved and then decrease subsequent doxorubicin total dose to 60 mg/m<sup>2</sup> per cycle.<sup>[1]</sup></li> <li>For grade 3 or 4 mucositis or diarrhea after methotrexate, consider leucovorin rescue dose adjustment.<sup>◊</sup><sup>[1]</sup> Also, maximize measures for methotrexate elimination. </li> <li>Refer to UpToDate topics on therapeutic use and toxicity of high-dose methotrexate.</li> <li>If grade 3 or 4 mucositis or diarrhea after methotrexate in week 4 (cycle 1) and it persists for longer than one week, omit week 5 methotrexate and proceed to week 6 of preoperative chemotherapy (or surgery).<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Nephrotoxicity</strong></td> <td colspan="4"> <ul> <li>Hold cisplatin if serum creatinine is greater than twice baseline or if GFR is &lt;70 mL/min/1.73 m<sup>2</sup>. If renal function does not improve, omit cisplatin and administer doxorubicin alone. Cisplatin can be restarted in future courses if GFR improves to ≥70 mL/min/1.73 m<sup>2</sup>.</li> <li>Hold methotrexate treatment if GFR is &lt;70 mL/min/1.73 m<sup>2</sup> until GFR is ≥70 mL/min/1.73 m<sup>2</sup>. If renal function does not improve within one week, then omit methotrexate and proceed to the next possible cycle. If renal function subsequently improves, resume methotrexate.<sup>[1]</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Peripheral neurotoxicity</strong></td> <td colspan="4"> <ul> <li>Neuropathy is usually seen with cumulative doses of cisplatin &gt;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. As per the original protocol, for grade 2 peripheral neurotoxicity, reduce cisplatin dose by 25% for all future courses; for ≥grade 3 peripheral neurotoxicity, omit cisplatin for all future cycles.<sup>[1]</sup></li> <li>Refer to UpToDate topics on overview of neurologic complications of platinum-based chemotherapy.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="5" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10% (except for cases of limb loss during surgery), doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; IM: intramuscular; microM: micromol/L; G-CSF: granulocyte colony-stimulating factors; WBC: white blood cell; ULN: upper limit of normal; LVEF: left ventricular ejection fraction; CBC: complete blood count; LFTs: liver function tests; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ANC: absolute neutrophil count; MUGA: multigated acquisition scan; GFR: glomerular filtration rate.<br/>
* Chemotherapy doses should be calculated according to presurgery body surface area (using actual body weight) with no adjustment for postoperative limb loss.<sup>[1]</sup><br/>
¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>
Δ Some pediatric centers limit the methotrexate dose to 20 grams,<sup>[4]</sup> regardless of the body surface area.<br/>
<span class="lozenge">◊</span> The reversal of methotrexate action by leucovorin is competitive. Therefore, proportionately higher leucovorin concentrations are required to achieve rescue in the presence of high methotrexate levels. Specific dose modification schemas for leucovorin vary widely among protocols and institutions, but most schemas utilized are derived from Bleyer WA.<sup>[5,6]</sup> Refer to UpToDate topic on "Therapeutic use and toxicity of high-dose methotrexate" for further information on leucovorin rescue and UpToDate table titled "Recommendations for dose adjustment of leucovorin (d,l-racemic mixture) for prolonged methotrexate excretion" as an example of leucovorin dose adjustment.</div><div class="graphic_reference">References:
<ol>
<li>Children's Oncology Group - Protocol AOST0331 (EURAMOS1): A phase III intergroup study; a randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy (<a href="https://www.clinicaltrials.gov/ct2/show/NCT00134030?term=AOST0331&amp;rank=1">http://www.clinicaltrials.gov/ct2/show/NCT00134030?term=AOST0331&amp;rank=1</a>, accessed December 17, 2012).</li>
<li>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://www.dailymed.nlm.nih.gov/dailymed/">dailymed.nlm.nih.gov</a>, accessed November 20, 2012).</li>
<li>Methotrexate. Cancer Care Ontario Drug Formulary. (Available online at <a href="http://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44166" target="_blank">http://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44166</a>, accessed August 20, 2019).</li>
<li>Meyers PA, et al. J Clin Oncol 2005; 23:2004.</li>
<li>Bleyer WA. Cancer Treat Rev 1977; 4:87.</li>
<li>Bleyer WA. Cancer 1978; 41:36.</li>
</ol></div><div id="graphicVersion">Graphic 87346 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
